These include i) antivirals against EBV; ii) small molecule inhibitors for EBV-encoded gene products, such as LMP1 and EBNAs; iii) induction of the lytic form of EBV replication in tumor cells in combination with prodrugs that are cytotoxic in lytically infected cancer cells; iv) enhancing the host immune response to viral antigens expressed by EBV-infected tumor cells; v) use of EBV vaccines. Here, PDLIM7 is linked to cancer.